advertisement
Vavvas DG 22
Showing records 1 to 22 | Display all abstracts from Vavvas DG104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Saini C
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Moos WH; Faller DV
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Chen TC; Young LH
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Glavas IP
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Vavvas DG
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Harpp DN; Kamperi N
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Vangel M; Papaliodis GN
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Kanara I; Kodukula K
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Mukai S; Turalba AV
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Mavrakis AN
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Rhee DJ
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Pernokas J; Pernokas M
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Wu DM; Eliott D
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Pinkert CA; Powers WR
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Miller JB
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Sampani K
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Song BJ; Shen LQ
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Steliou K
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Pasquale LR
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Tamvakopoulos C; Vavvas DG
Biochemical Pharmacology 2022; 203: 115168
104671 Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
Chodosh J
American Journal of Ophthalmology 2022; 243: 42-54
104635 Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Zamboni RJ; Chen X
Biochemical Pharmacology 2022; 203: 115168
